Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

por Khatri, Amit, Suleiman, Ahmed A., Polepally, Akshanth R., Othman, Ahmed A.
Publicado 2019

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

por Winzenborg, Insa, Polepally, Akshanth R., Nader, Ahmed, Mostafa, Nael M., Noertersheuser, Peter, Ng, Juki
Publicado 2020

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

por Badri, Prajakta S., King, Jennifer R., Polepally, Akshanth R., McGovern, Barbara H., Dutta, Sandeep, Menon, Rajeev M.
Publicado 2015

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

por Abbas Suleiman, Ahmed, Nader, Ahmed, Winzenborg, Insa, Beck, Denise, Polepally, Akshanth R., Ng, Juki, Noertersheuser, Peter, Mostafa, Nael M.
Publicado 2020

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

por Stodtmann, Sven, Nader, Ahmed, Polepally, Akshanth R., Suleiman, Ahmed A., Winzenborg, Insa, Noertersheuser, Peter, Ng, Juki, Mostafa, Nael M., Shebley, Mohamad
Publicado 2021

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

por Shebley, Mohamad, Polepally, Akshanth R., Nader, Ahmed, Ng, Juki W., Winzenborg, Insa, Klein, Cheri E., Noertersheuser, Peter, Gibbs, Megan A., Mostafa, Nael M.
Publicado 2019

Model-based lamotrigine clearance changes during pregnancy: clinical implication

por Polepally, Akshanth R, Pennell, Page B, Brundage, Richard C, Stowe, Zachary N, Newport, Donald J, Viguera, Adele C, Ritchie, James C, Birnbaum, Angela K
Publicado 2014

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist

por Polepally, Akshanth R., Ng, Juki W., Salem, Ahmed Hamed, Dufek, Matthew B., Parikh, Apurvasena, Carter, David C., Kamradt, Kent, Mostafa, Nael M., Shebley, Mohamad
Publicado 2020

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION

por Valdes, Cesar Rodriguez, Weisel, Katja, Baz, Rachid, Polepally, Akshanth, Ross, Jeremy A., Jin, Ziyi, D’amico, Kristin, Bueno, Orlando F., Fleming, Leanne Lash, Voorhees, Peter
Publicado 2023

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

por Badri, Prajakta S., Dutta, Sandeep, Wang, Haoyu, Podsadecki, Thomas J., Polepally, Akshanth R., Khatri, Amit, Zha, Jiuhong, Chiu, Yi-Lin, Awni, Walid M., Menon, Rajeev M.
Publicado 2015

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers...

por Polepally, Akshanth R., King, Jennifer R., Ding, Bifeng, Shuster, Diana L., Dumas, Emily O., Khatri, Amit, Chiu, Yi-Lin, Podsadecki, Thomas J., Menon, Rajeev M.
Publicado 2016

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis

por Poordad, Fred, Sedghi, Shahriar, Pockros, Paul J., Ravendhran, Natarajan, Reindollar, Robert, Lucey, Michael R., Epstein, Michael, Bank, Leslie, Bernstein, David, Trinh, Roger, Krishnan, Preethi, Polepally, Akshanth R., Unnebrink, Kristina, Martinez, Marisol, Nelson, David R.
Publicado 2019

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

por D'Souza, Anita, Shah, Nina, Rodriguez, Cesar, Voorhees, Peter M., Weisel, Katja, Bueno, Orlando F., Pothacamury, Rajvineeth K., Freise, Kevin J., Yue, Susan, Ross, Jeremy A., Polepally, Akshanth R., Talati, Chetasi, Lee, Shane, Jin, Ziyi, Buelow, Ben, Vij, Ravi, Kumar, Shaji
Publicado 2022